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Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas
(NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I
EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a
clinically representative cohort of endometrial carcinomas.
Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of
the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive
when 410% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological
characteristics and disease outcome was calculated.
Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104
NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid
histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the
NEECs.
Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated
with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial
carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
Endometrial carcinoma is the most common gynaecological
malignancy in developed countries (Siegel et al, 2012). These
carcinomas can be histologically classified as either endometrioid
endometrial carcinomas (EECs) or non-endometrioid endometrial
carcinomas (NEECs) (Lax, 2004; Matias-Guiu and Prat, 2013). In
general, EECs have a favourable prognosis, and are characterised
by expression of the oestrogen and progesterone receptors,
microsatellite instability, and PTEN, KRAS, PIK3CA, and CTNNB1
mutations. The most common NEECs have serous or clear cell
histology, and a worse prognosis. They are characterised by TP53
mutations, and PTEN and PIK3CA mutations, respectively. Less
common carcinomas with non-endometrioid histology are those
with undifferentiated histology, characterised by microsatellite
instability, those with mucinous histology, with a prognosis and
molecular characterisation similar to EECs, and the carcinosarco-
mas. However, a substantial number of endometrial carcinomas do
not fit within this dualistic model, and have mixed histology or
hybrid molecular and histological characteristics, making diagnosis
challenging (Matias-Guiu and Prat, 2013). After primary surgery,
adjuvant treatment is recommended based on the presence of
predictors of poor outcome, most importantly FIGO stage.
In addition, the prognosis is related to histological type, tumour
grade, myometrial invasion, lymphovascular space invasion
(LVSI), and the age of the patient (Amant et al, 2015). More
recently, a new subdivision into four subgroups, based on the
molecular profile, was proposed by The Cancer Genome Atlas
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Research network (Cancer Genome Atlas Research Network et al,
2013). However, these data have not been incorporated in clinical
practice yet. In addition, several immunohistochemical markers
have been shown to be associated with poor outcome. Expression
of the transmembrane L1 cell adhesion molecule (L1CAM) seems
to be one of the most powerful ones described to date. The L1CAM
plays an important role in neurogenesis, but has been associated
with poor outcome in various cancer types (Fogel et al, 2003;
Allory et al, 2005; Boo et al, 2007; Schroder et al, 2009; Tischler
et al, 2011; Tsutsumi et al, 2011; Bondong et al, 2012; Schafer and
Frotscher, 2012; Wang et al, 2013). Two large studies have shown a
strong association between L1CAM expression in stage I EEC and
poor disease outcome (Zeimet et al, 2013; Bosse et al, 2014).
However, there was a wide variation in both the percentage of cases
expressing L1CAM and the strength of the association between
L1CAM and disease outcome found by these studies. More
recently, several smaller studies have highlighted the association
between L1CAM expression and poor disease outcome in
advanced-stage EECs and NEECs, as well as a strong association
between L1CAM expression and non-endometrioid histology
(Dellinger et al, 2016; Geels et al, 2016; Van Gool et al, 2016).
However, these studies have limited clinical applicability because
neither of these studies analysed the subgroups separately, and the
number of included advanced-stage EECs and NEECs is still
limited. In addition, Dellinger et al (2016) used mRNA L1CAM
expression with a different cutoff than the other studies that limits
the comparability.
The aim of the current study is therefore to analyse the value of
immunohistochemical L1CAM expression in a large, clinically
representative cohort of endometrial carcinomas, including sub-
stantial numbers of all histological types and FIGO stages.
MATERIALS AND METHODS
Patients. This study was performed within the European Network
for Individualized Treatment of Endometrial Cancer (ENITEC), a
European Society of Gynecological Oncology (ESGO) consortium
aiming to improve and individualise treatment of women with
uterine cancers by sharing expertise. All ENITEC members were
invited to participate in this study and to include patients treated
for stage I EEC (a maximum of 150 cases per centre), stage II–IV
EEC, or NEEC. Cases with any non-endometrioid component were
included in the NEEC group, except for the mucinous carcinomas
that were included in the EEC groups as their characteristics
and prognosis are similar to that of endometrioid carcinomas
(Lax, 2004). Only cases diagnosed by an expert gynecological
pathologist, with complete data on treatment and pathology, and at
least 36 months of follow-up were included. Clinical and
pathological data were recorded from the patient files into a
database, including patient age, date of diagnosis, surgical
treatment (including lymphadenectomy and omentectomy),
tumour histology and grade, myometrial invasion, cervical
invasion, LVSI, FIGO stage, adjuvant treatment (including radio-
therapy, chemotherapy and chemoradiation), residual disease,
recurrent disease, and death.
Tissue and staining. One representative slide was selected per
case. Blank 4 mm sections, cut from the corresponding formalin-
fixed, paraffin-embedded tissue blocks, on Superfrost slides were
sent to the Radboud University Medical Center. A haematoxylin
and eosin and an immunohistochemically stained L1CAM slide
were made for every case. Immunohistochemical staining was
performed in semiautomatic staining devices using an optimised
version of the previously described staining protocol (Fogel et al,
2014). In short, after EDTA antigen retrieval and blocking of
endogenous peroxidase with hydrogen peroxide, slides were
incubated with 1 : 100 diluted L1CAM antibody (purified anti-
CD171 (L1) antibody clone 14.10, Biolegend, San Diego, CA,
USA). They were subsequently incubated with PowerVisionþ
Poly-HRP and visualised with PowerVision DAB substrate
solution (Leica Biosystems, Buffalo Grove, IL, USA). Finally, the
slides were counterstained with haematoxylin, dehydrated, and
mounted. Staining of the nerves was used as internal positive
control.
Scoring. All slides were scored twice, by independent pathologists.
First by NCM Visser or K van de Vijver, and subsequently by
M Santacana, P Bronsert or J Bulten. They were blinded for clinical
and pathological data, as well as each other’s scores. They were
asked to score the number of stained tumour cells as 0%, 1–10%
11–50%, or 51–100%, and cases were considered to express
L1CAM when one or both pathologists considered 410% of the
tumour cells to be stained, in accordance with the previously
described cutoff (Zeimet et al, 2013; Bosse et al, 2014; Geels et al,
2016). Cohen’s k was calculated for L1CAM expression as
a dichotomous variable (either p10% or 410%). In case of large
discrepancies (i.e., if one pathologist scored 0% and the other
11–100%, or if one pathologist scored 1–10% and the other
51–100%) the slides were reviewed by a third pathologist who did
not score the slide initially (either NCM Visser or J Bulten).
Statistical analysis. Clinicopathological differences between
L1CAM-positive and -negative cases were compared using the
w2 and Fisher’s exact tests for categorical variables and the Mann–
Whitney U-test for continuous variables, and corresponding
P-values are shown in Tables 1–4.
The association between L1CAM expression and other known
risk factors expressed as an odds ratio (OR) and corresponding
95% confidence interval (95% CI) was calculated using univariate
logistic regression analysis. These risk factors were deep myome-
trial invasion, patient age over 60 years, LVSI, non-endometrioid
(except mucinous) histology, advanced FIGO stage, and nodal
involvement.
The Kaplan–Meier curves of 10-year disease-free and overall
survival were generated for the stage I EEC, stage II–IV EEC,
and NEEC subgroups. The corresponding hazard ratio (HR) and
95% CI was calculated using Cox regression analysis. For stage I
EECs a multivariate analysis was performed including covariates
that were significantly associated with outcome in the univariate
analysis. Sample size calculation accounted only for multivariate
Cox regression analysis of the stage I EECs.
Statistical differences were considered significant at a two-sided
P-value of p0.05. SPSS version 22 (SPSS IBM, New York, NY,
USA) statistical software was used to perform the statistical
analyses.
Ethical approval. The study was approved by the institutional
review board (IRB) of all participating centres.
RESULTS
L1CAM in endometrial carcinomas. There were 1199 cases
included from 10 European centres, including 935 stage I EECs,
160 stage II–IV EECs, and 104 NEECs. The L1CAM was expressed
in 200 (17%) cases, and was scored with a k of 0.82. Table 1 shows
demographic and tumour characteristics of all cases and a
comparison between the L1CAM-negative and -positive cases.
These two groups were significantly different concerning demo-
graphics, treatment, tumour characteristics, and disease outcome.
In univariate regression analysis, L1CAM expression was
significantly associated with advanced stage (OR 5.1, 95%
CI 3.5–7.3), nodal involvement (OR 5.0, 95% CI 3.2–7.7), and
non-endometrioid histology (OR 24.0, 95% CI 14.8–38.8).
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L1CAM in stage I endometrioid endometrial carcinomas.
Patient and tumour characteristics of all stage I EEC cases
(n¼ 935, including 4 mucinous carcinomas) with respect to
L1CAM expression are shown in Table 2. The L1CAM was
expressed in 93 (10%) cases. These patients were older, had a
higher tumour grade and LVSI, and more often presented with
distant recurrence and disease-related mortality.
In univariate regression analysis, L1CAM expression was
significantly associated with grade 3 histology (OR 4.1, 95%
CI 2.5–6.8) and LVSI (OR 2.9, 95% CI 1.5–5.6), but not with deep
myometrial invasion.
L1CAM in advanced-stage endometrioid endometrial carcino-
mas. Patient and tumour characteristics of all advanced-stage EEC
cases (n¼ 160, including 5 mucinous carcinomas) with respect to
L1CAM expression are shown in Table 3. The expression of
L1CAM was present in 28 (18%) cases. These cases had a higher
tumour grade, a more advanced FIGO stage, and more often
presented with distant recurrence and disease-related mortality.
In univariate regression analysis, L1CAM expression was
significantly associated with the presence of nodal disease
(OR 4.1, 95% CI 1.5–11.5) and LVSI (OR 3.0, 95% CI 1.1–8.0).
L1CAM in non-endometrioid carcinomas. Patient and tumour
characteristics of all NEEC cases (n¼ 104) with respect to L1CAM
expression are shown in Table 4. The expression of L1CAM was
present in 78 (75%) cases, and varied between the subgroups: 77%
of the serous carcinomas, 82% of the clear cell carcinomas, 64% of
the carcinosarcomas, and 57% of the undifferentiated carcinomas
expressed L1CAM. Patients with L1CAM expression were older,
more often had LVSI, and more often presented with distant
recurrences and disease-related mortality.
In univariate regression analysis, L1CAM expression was
significantly associated with the presence of LVSI (OR 4.6, 95%
CI 1.5–14.1).
L1CAM expression and survival. The 10-year disease-free and
overall survival Kaplan–Meier plots are shown in Figure 1.
Corresponding HRs are shown in Table 5.
Multivariate analysis of the stage I EEC cases showed that
expression of L1CAM is a strong and independent predictor of
both reduced disease-free survival and overall survival, along with
several known prognostic markers. Patient age of 460 years was
the strongest predictor of reduced overall survival, but not of
reduced disease-specific survival (data not shown).
The expression of L1CAM and the presence of LVSI in
advanced-stage EEC cases were significantly associated with
reduced disease-free, and overall survival in univariate analysis.
Grade 3 histology and deep myometrial invasion predicted a
reduced overall survival as well, but the myometrial invasion
HR had a very wide CI.
Analysis of the NEEC cases showed that L1CAM expression is
not associated with reduced disease-free and overall survival.
Patient age of460 years and advanced FIGO stage were associated
Table 1. Comparison of the clinical and pathologic characteristics and disease outcome of all included carcinomas with respect to
the L1CAM expression
All L1CAM L1CAMþ Pa
Number of patients 1199 999 (83%) 200 (17%)
Median age (years) 64 (range 31–93) 63 (range 31–93) 69 (range 39–93) o0.01
Median follow-upb (months) 62 (range 0–229) 64 (1–229) 50 (range 0–185) o0.01
Treatment
Lymphadenectomy 795 (66%) 645 (65%) 150 (75%) o0.01
Radiotherapy 563 (47%) 467 (47%) 96 (48%) 0.86
Chemotherapy 123 (10%) 72 (7%) 51 (26%) o0.01
FIGO stage
I 965 (80%) 849 (85%) 116 (58%) o0.01
II 74 (6%) 58 (6%) 16 (8%)
III 125 (10%) 76 (8%) 49 (25%)
IV 35 (3%) 16 (2%) 19 (10%)
Histology
Endometrioid 1095 (91%) 973 (97%) 122 (61%) o0.01
Non-endometrioid 104 (9%) 26 (3%) 78 (39%)
Grade
1 467 (39%) 441 (44%) 26 (13%) o0.01
2 474 (40%) 417 (42%) 57 (29%)
3 258 (22%) 141 (14%) 117 (59%)
Myometrial invasion
o1/2 746 (62%) 656 (66%) 90 (45%) o0.01
X1/2 453 (38%) 343 (34%) 110 (55%)
LVSI
No 813 (68%) 723 (88%) 90 (60%) o0.01
Yes 162 (14%) 101 (12%) 61 (41%)
Unknown 224 175 49
Outcome
Residual disease 40 (3%) 15 (2%) 25 (12.5%) o0.01
Recurrence 158 (13%) 100 (10%) 58 (33%) o0.01
Locoregional 76 (7%) 57 (6%) 19 (11%) 0.02
Distant 98 (8%) 53 (5%) 45 (26%) o0.01
Deceased 171 (14%) 104 (10%) 67 (34%) o0.01
Endometrial cancer 99 (8%) 48 (5%) 51 (26%) o0.01
Abbreviations: FIGO¼ International Federation of Gynaecology and Obstetrics; L1CAM¼ L1 cell adhesion molecule; LVSI¼ lymphovascular space invasion.
aP-value for the Mann–Whitney U-test for continuous variables, and w2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
bMedian follow-up including deceased patients.
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with reduced disease-free survival, and the presence of LVSI and
advanced FIGO stage were associated with reduced overall survival.
DISCUSSION
This large, well-documented series of 1199 endometrial carcinomas
shows a strong association between L1CAM expression and poor
outcome in stage I EECs and advanced-stage EECs, but not in
NEECs. Moreover, L1CAM expression was shown to be associated
with the presence of nodal disease, grade 3 histology, LVSI, and
distant disease recurrences, but especially with non-endometrioid
histology.
Prognostic value of L1CAM expression in stage I endometrioid
carcinomas. Two large studies have described the prognostic value
of L1CAM expression in stage I EECs. Zeimet et al (2013) found
L1CAM expression in 17% of the cases, with HRs of 16.33 for
recurrence and 15.01 for death. The PORTEC group found
L1CAM expression in 7%, with HRs of 2.55 for pelvic recurrence,
3.48 for distant recurrence, and 2.05 for death (Bosse et al, 2014).
In comparison, we found L1CAM expression in 10% of the stage I
EECs, with HRs of 2.3 for recurrences, 2.8 for distant recurrences,
and 2.4 for death.
The number of lymphadenectomies performed in our study was
slightly higher than in the Zeimet study. The PORTEC study does
not mention the exact number of lymphadenectomies, but it is
described that routine lymphadenectomies were not performed,
and only suspicious nodes were removed. Patients in our study
received radiotherapy, especially external beam radiotherapy, more
often than patients in the Zeimet study, but less often than those in
the PORTEC study. Patients in the PORTEC study more often had
a low-grade tumour and deep myometrial invasion that was related
to the inclusion criteria of the study. In the Zeimet study LVSI was
present in a large number of carcinomas compared with both our
study and the PORTEC study.
It was hypothesised that a lower number of included grade 1
cases might explain the higher number of L1CAM-positive cases in
the Zeimet study (Bosse et al, 2014). Although we show a strong
association between L1CAM expression and grade 3 histology, our
study included even fewer grade 1 cases, making it unlikely that
this explains the difference in L1CAM expression. As we show a
strong association between the presence of L1CAM expression and
LVSI, it is possible that the high prevalence of LVSI in the Zeimet
study is responsible for the high number of L1CAM-positive cases,
and the exceptionally strong association between L1CAM expres-
sion and poor outcome they describe.
Several smaller studies included stage I EECs in addition to
advanced-stage EECs and NEECs. Unfortunately, both Van Gool
et al (2016) and Geels et al (2016) did not analyse the value of
L1CAM expression specifically in the stage I EECs, making it
impossible to compare our findings with these studies. Interest-
ingly, Dellinger et al (2016) included a sizeable amount of stage I
EECs and analysed the association between mRNA expression of
L1CAM and prognosis, but were not able to validate the strong
prognostic value of L1CAM expression. This might be explained by
the fact that they considered all cases with an mRNA L1CAM
expression above the median to be positive, resulting in a much
higher proportion of L1CAM-positive cases in their study
compared with other L1CAM studies.
Prognostic value of L1CAM expression in advanced-stage
endometrioid carcinomas and non-endometrioid carcinomas.
Several previous studies described the prognostic value of L1CAM
expression in advanced-stage EECs and NEECs. Fogel et al (2003)
described L1CAM expression in all of the 10 included FIGO stage
III and IV cases, but the histology was not mentioned, and 3
previous studies described L1CAM expression in 73% of the 15,
Table 2. Comparison of the clinical and pathologic characteristics as well as disease outcome of stage I endometrioid
endometrial carcinomas with respect to L1CAM expression
All L1CAM L1CAMþ Pa
Number of patients 935 842 (90%) 93 (10%)
Median age (years) 63 (range 32–93) 63 (range 32–91) 67 (range 39–93) o0.01
Median follow-upb (months) 64 (range 1–210) 65 (range 1–210) 55 (range 6–185) o0.01
Treatment
Lymphadenectomy 586 (63%) 519 (62%) 67 (72%) 0.05
Radiotherapy 400 (43%) 359 (43%) 41 (44%) 0.79
VBT 206 (22%) 189 (23%) 17 (18%)
EBRTþ /VBT 190 (20%) 166 (20%) 24 (26%)
Chemotherapy 36 (4%) 31 (4%) 5 (5%) 0.42
Grade
1 442 (47%) 418 (50%) 24 (26%) o0.01
2 389 (42%) 348 (41%) 41 (44%)
3 104 (11%) 76 (9%) 28 (30%)
Myometrial invasion
o1/2 664 (71%) 604 (72%) 60 (65%) 0.15
X1/2 271 (29%) 238 (28%) 33 (36%)
LVSI
No 703 (91%) 645 (92%) 58 (81%) o0.01
Yes 67 (9%) 53 (8%) 14 (19%)
Unknown 165 144 21
Outcome
Recurrence 85 (9%) 66 (8%) 19 (20%) o0.01
Locoregional 48 (5%) 41 (5%) 7 (8%) 0.27
Distant 42 (5%) 29 (3%) 13 (14%) o0.01
Deceased 88 (9%) 69 (8%) 19 (20%) o0.01
Endometrial cancer 37 (4%) 26 (3%) 11 (12%) o0.01
Abbreviations: EBRT¼ external beam radiotherapy; L1CAM¼ L1 cell adhesion molecule; LVSI¼ lymphovascular space invasion; VBT¼ vaginal brachytherapy.
aP-value for the Mann–Whitney U-test for continuous variables, and w2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
bMedian follow-up including deceased patients.
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58% of the 12, and 55% of the 20 included NEEC cases (Zeimet
et al, 2013; Bosse et al, 2014). We found L1CAM expression in 75%
of the 104 NEEC cases.
Three studies included both advanced-stage EECs and NEECs
and described the association between L1CAM expression and
clinicopathological variables, as well as between L1CAM expression
and outcome (Dellinger et al, 2016; Geels et al, 2016;
Van Gool et al, 2016). Geels et al (2016) found an association
between L1CAM expression and high tumour grade and LVSI,
Dellinger et al (2016) between L1CAM expression and advanced
FIGO stage, non-endometrioid histology, high tumour grade, deep
myometrial invasion, and nodal spread, and Van Gool et al (2016)
between L1CAM expression and non-endometrioid histology and
high tumour grade, but not FIGO stage, depth of myometrial
invasion, and LVSI. In comparison, we found an association between
L1CAM expression and advanced FIGO stage, non-endometrioid
histology, high tumour grade, LVSI, and nodal spread. We found
these associations in all three subgroups, but unfortunately neither of
these studies analysed the association between L1CAM and
clinicopathological variables within the subgroups.
In addition, neither of these studies analysed the disease-free
and overall survival separately in the advanced-stage EECs and
NEECs. Our subgroup analyses have shown that there is indeed a
strong association between L1CAM expression and poor outcome
in the advanced-stage EECs, but not in the NEECs, possibly
because the presence of non-endometrioid histology itself is a
strong marker of poor prognosis, and the majority were L1CAM
positive. The fact that previous studies have combined the
advanced-stage EECs and the NEECs in the high-risk carcinoma
group might therefore have influenced their results, and additional
studies are required to validate the prognostic value of L1CAM
expression separately in the advanced-stage EECs and the NEECs.
This study shows that there is a very strong association between
L1CAM expression and the presence of non-endometrioid
histology. Up until now, p53 expression has been used to identify
NEECs, and whereas p53 is frequently expressed in serous
carcinomas, it does not play an important role in other NEECs
(Lax, 2004). Previous studies reported p53 expression in 62–67% of
all NEECs, whereas we found L1CAM expression in 75% of the
NEECs, including 77% of the serous and 82% of the clear cell
carcinomas (Engelsen et al, 2006; Van Gool et al, 2016). Based on
these findings L1CAM expression appears to be the most powerful
marker to identify NEECs described to date.
Interestingly, Van Gool et al (2016) did not find an association
between L1CAM expression with a cutoff of 10% and poor
outcome in their cohort of high-risk carcinomas, including high-
risk stage I EECs, but did find this association when using a cutoff
of 50%. We however did find an association between L1CAM
expression with a cutoff of 10% and poor outcome in the
advanced-stage EECs and NEECs, and preliminary analyses did
not show a major advantage of using a higher cutoff (data not
shown). Using one cutoff in all subgroups would be preferable,
because having to determine the tumour histology, tumour grade,
and the depth of myometrial invasion before choosing the L1CAM
cutoff would greatly limit the clinical applicability.
It has to be noted that mixed carcinomas were included in the
NEEC group of our study, and pure non-endometrioid histology
was more common in the L1CAM-positive cases. There is a
Table 3. Comparison of the clinical and pathologic characteristics as well as disease outcome of advanced-stage endometrioid
endometrial carcinoma cases with respect to L1CAM expression
All L1CAM L1CAMþ Pa
Number of patients 160 131 (82%) 29 (18%)
Median age (years) 64 (range 37–93) 64 (range 37–93) 68 (range 47–84) 0.40
Median follow-upb (months) 55 (range 1–227) 58 (range 3–227) 37 (range 1–106) o0.01
Treatment
Lymphadenectomy 122 (76%) 103 (79%) 19 (65%) 0.13
Radiotherapy 112 (80%) 95 (73%) 17 (59%) 0.14
Chemotherapy 41 (26%) 31 (24%) 10 (36%) 0.23
Chemoradiotherapy 7 (5%) 6 (5%) 1 (4%) 1.00
FIGO stage
II 59 (37%) 54 (41%) 5 (18%) 0.02
III 83 (52%) 62 (47%) 21 (72%) 0.02
IV 18 (12%) 15 (12%) 3 (11%) 1.00
Grade
1 25 (16%) 23 (18%) 2 (7%) 0.20
2 82 (51%) 68 (52%) 14 (48%)
3 53 (33%) 40 (31%) 13 (45%)
Myometrial invasion
o1/2 43 (27%) 39 (30%) 4 (14%) 0.11
X1/2 117 (73%) 92 (70%) 25 (86%)
LVSI
No 67 (54%) 60 (59%) 7 (33%) 0.052
Yes 58 (46%) 43 (42%) 15 (68%)
Unknown 35 28 7
Outcome
Residual disease 19 (12%) 13 (10%) 6 (21%) 0.12
Recurrence 41 (26%) 28 (24%) 13 (57%) o0.01
Locoregional 15 (9%) 12 (10%) 3 (13%) 0.71
Distant 31 (19%) 20 (17%) 11 (48%) o0.01
Deceased 38 (24%) 25 (19%) 13 (45%) o0.01
Endometrial cancer 26 (16%) 16 (12%) 10 (35%) o0.01
Abbreviations: FIGO¼ International Federation of Gynaecology and Obstetrics; L1CAM¼ L1 cell adhesion molecule; LVSI¼ lymphovascular space invasion.
aP-value for the Mann–Whitney U-test for continuous variables, and w2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
bMedian follow-up including deceased patients.
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possibility that mixed cases with a large endometrioid component
were considered L1CAM negative in our study, even though
L1CAM was expressed in over 10% of the non-endometrioid
component.
Relationship between these findings and the function of
L1CAM. The L1CAM was shown to have several extracellular
and intracellular functions in cancer, both in an intact and cleaved
form, as it has an influence on cell migration, cell survival,
angiogenesis, and tumour progression (Mechtersheimer et al, 2001;
Shtutman et al, 2006; Sebens Muerkoster et al, 2007; Stoeck et al,
2007; Gast et al, 2008a, b; Friedli et al, 2009). It is known that
epithelial-to-mesenchymal transition (EMT) plays an important
role in endometrial cancer invasion and metastasis (Colas et al,
2012). Several studies suggest that L1CAM expression induces an
EMT-like transition that increases the metastatic potential, without
altering the invasive capabilities. Comparable to EMT, expression
of L1CAM was shown to be TGFb and Slug dependent
(Geismann et al, 2009; Huszar et al, 2010). Moreover, several
studies have shown that intracellular L1CAM signalling activates
NF-kB that was shown to be essential for EMT and metastasis of
breast cancer (Huber et al, 2004; Gavert et al, 2010; Kiefel et al,
2012). In colorectal cancer cell lines, L1CAM expression was
shown to increase cell motility and liver metastasis, without
changes in expression of epithelial or mesenchymal markers.
Introduction of major EMT regulators changed expression of
epithelial and mesenchymal markers, but did not increase the
metastatic potential (Gavert et al, 2011). Many clinical studies
have shown that there is a strong association between L1CAM
expression and metastasis in various cancer types (Allory et al,
2005; Boo et al, 2007; Schroder et al, 2009; Tischler et al, 2011;
Tsutsumi et al, 2011; Bondong et al, 2012; Wang et al, 2013). The
current study shows a comparable association between L1CAM
expression and advanced stage, lymph node involvement, and
metastasis in both EECs and NEECs. Interestingly, there was no
strong association between L1CAM expression and myometrial and
cervical invasion, and although it was not scored separately in our
study, the pathologists did not notice a clear localisation of L1CAM at
the invasive front of the carcinomas. These findings are in accordance
with the hypothesis that L1CAM induces EMT-like changes, but only
plays a role in metastasis, and not invasion.
However, several previous studies analysing the association
between L1CAM expression and clinicopathological variables present
conflicting results concerning whether or not there is an association
between L1CAM expression and the presence of LVSI, deep
myometrial invasion, and cervical invasion (Zeimet et al, 2013;
Bosse et al, 2014; Dellinger et al, 2016; Geels et al, 2016; Van Gool
et al, 2016). Future studies focussing on the function of L1CAM will
likely provide more insight into the possible association between
L1CAM and these processes of invasion and metastasis.
Table 4. Comparison of the clinical and pathologic characteristics as well as disease outcome of the non-endometrioid carcinoma
cases with respect to L1CAM expression
All L1CAM L1CAMþ Pa
Number of patients 104 26 (25%) 78 (75%)
Median age (years) 69 (range 31–88) 64 (range 31–83) 70 (range 49–88) o0.01
Median follow-upb (months) 46 (range 0–229) 52 (range 2–229) 45 (range 0–129) 0.15
Treatment
Lymphadenectomy 87 (84%) 23 (89%) 64 (82%) 0.56
Radiotherapy 51 (49%) 13 (50%) 38 (49%) 0.91
Chemotherapy 46 (44%) 10 (39%) 36 (46%) 0.50
FIGO stage
I 30 (39%) 7 (27%) 23 (30%) 0.73
II 15 (14%) 4 (15%) 11 (14%) 1.00
III 42 (40%) 14 (54%) 28 (36%) 0.11
IV 17 (16%) 1 (4%) 16 (21%) 0.06
Histology
Pure NEEC 76 (73%) 17 (65%) 59 (76%) 0.32
Mixed EEC/NEEC 28 (27%) 9 (35%) 19 (24%)
Primary NEEC component
Serous 61 (59%) 14 (54%) 47 (60%) 0.57
Clear cell 22 (21%) 4 (15%) 18 (23%) 0.58
Carcinosarcoma 14 (14%) 5 (19%) 9 (12%) 0.33
Undifferentiated 7 (7%) 3 (12%) 4 (5%) 0.36
Myometrial invasion
o1/2 39 (38%) 13 (50%) 26 (33%) 0.13
X1/2 65 (63%) 13 (50%) 52 (67%)
LVSI
No 43 (54%) 18 (78%) 25 (44%) o0.01
Yes 37 (46%) 5 (22%) 32 (56%)
Unknown 24 3 21
Outcome
Residual disease 21 (20%) 2 (8%) 19 (24%) 0.09
Recurrence 32 (39%) 6 (25%) 26 (44%) 0.14
Locoregional 13 (16%) 4 (17%) 9 (15%) 1.00
Distant 25 (30%) 4 (17%) 21 (36%) 0.12
Deceased 45 (43%) 10 (39%) 35 (45%) 0.57
Endometrial cancer 36 (35%) 6 (23%) 30 (39%) 0.23
Abbreviations: EEC¼ endometrioid endometrial carcinoma; FIGO¼ International Federation of Gynaecology and Obstetrics; L1CAM¼ L1 cell adhesion molecule; LVSI¼ lymphovascular space
invasion; NEEC¼ non-endometrioid carcinoma.
aP-value for the Mann–Whitney U-test for continuous variables, and w2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
bMedian follow-up including deceased patients.
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Future perspectives. Accumulating data associating L1CAM
expression in stage I EECs with a poor outcome should have
treatment implications. Moreover, this study shows that L1CAM
expression in advanced-stage EECs is associated with poor
outcome as well, and there was a trend towards more residual
disease after treatment, in line with L1CAM expression in ovarian
carcinoma that has been associated with restricted tumour
resectability (Bondong et al, 2012). Although this would seem to
support the use of chemotherapy, L1CAM expression in other
cancer types has been shown to be associated with chemotherapy
resistance (Sebens Muerkoster et al, 2007; Stoeck et al, 2007;
Bondong et al, 2012). Given the fact that a substantial number of
advanced-stage EECs and the majority of the NEECs are L1CAM
positive, and a growing number of these carcinomas are treated
with chemotherapy, studying the issue of resistance of L1CAM-
positive tumours to chemotherapy has a high priority. In addition,
the use of anti-L1CAM treatment might be an interesting future
option (Knogler et al, 2007).
This study also found a strong association between L1CAM
expression and the presence of other markers of poor prognosis,
most notably non-endometrioid histology, grade 3 histology, and
nodal disease. Once it is established that L1CAM expression in
preoperative biopsies is in accordance with final pathology,
incorporation into currently used preoperative prediction models
might improve the selection of patients requiring a lymphade-
nectomy, and help pathologists to identify high-risk carcinomas,
especially those with non-endometrioid histology.
In light of the recently proposed subdivision of endometrial
carcinomas into four subgroups based on the molecular profile, it
would be interesting to analyse the L1CAM expression in these
four groups (Cancer Genome Atlas Research Network et al, 2013).
The studies of both Dellinger et al (2016) and Van Gool et al
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Figure 1. Kaplan–Meier plots of the 10-year disease-free and overall survival of the stage I endometrioid, advanced-stage endometrioid, and
non-endometrioid cases with respect to L1CAM expression (a full colour version of this figure appears online).
Table 5. Results of the Cox regression analysis, depicting the association between several risk factors and outcome
Stage I EEC Stage II–IV EEC NEEC
Univariate Multivariate Univariate Univariate
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
DFS
L1CAMþ 3.1 (1.9–5.1) 2.3 (1.3–4.1) 3.9 (2.0–7.7) 2.0 (0.8–4.8)
Grade 3 2.7 (1.6–4.4) 2.0 (1.1–3.5) 1.3 (0.7–2.5) —
MI 450% 1.5 (1.0–2.3) — 1.8 (0.8–4.0) 1.1 (0.6–2.7)
Age 460 2.0 (1.2–3.3) 2.0 (1.1–3.4) 1.3 (0.7–2.6) 4.2 (1.0–17.7)
LVSI 2.9 (1.6–5.1) 2.3 (1.3–4.1) 3.1 (1.5–6.7) 1.8 (0.8–4.1)
FIGO 3/4 — — 1.6 (0.8–3.2) 2.6 (1.3–5.4)
OS
L1CAMþ 3.1 (1.9–5.2) 2.4 (1.4–4.2) 3.7 (1.9–7.3) 1.6 (0.8–3.3)
Grade 3 2.8 (1.7–4.6) 2.1 (1.1–3.6) 2.7 (1.4–5.1) —
MI 450% 1.3 (0.8–2.0) — 7.7 (1.9–32.0) 1.4 (0.8–2.7)
Age 460 2.8 (1.6–4.8) 2.9 (1.6–5.3) 2.0 (0.9–4.2) 1.7 (0.7–4.1)
LVSI 2.4 (1.3–4.4) 1.9 (1.0–3.4) 3.0 (1.4–6.2) 2.3 (1.1–4.7)
FIGO 3/4 — — 1.6 (0.8–3.4) 3.7 (1.8–7.5)
Abbreviations: CI¼ confidence interval; DFS¼disease-free survival; EEC¼endometrioid endometrial carcinoma; FIGO¼ International Federation of Gynaecology and Obstetrics; HR¼ hazard
ratio; L1CAM¼ L1 cell adhesion molecule; LVSI¼ lymphovascular space invasion; MI¼myometrial invasion; NEEC¼ non-endometrioid carcinoma; OS¼overall survival. The table shows hazard
ratios and corresponding 95% confidence intervals. Bold hazard ratios are significantly associated with the respective outcome variable. For the stage I EEC subgroup, additional multivariate
Cox regression analysis was performed, including covariates that were significantly associated with outcome in the univariate analysis.
L1CAM expression in endometrial carcinomas BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.235 7
(2016) looked at L1CAM expression in the mRNA data from the
TGCA database, but unfortunately they did not describe the
expression of L1CAM relative to the four proposed subgroups. If
either L1CAM expression or the proposed genetic subdivision
are to be used in the future management of endometrial
carcinomas, it is imperative to know how these markers are
related to each other.
Strengths and weaknesses. This is the largest study to date
including all endometrial carcinoma types. Complete surgical
staging was performed in the majority of cases, limiting the risk of
under diagnosis, and a minimal follow-up of 36 months was
required, limiting the risk of missing disease recurrences and
deaths. As this was a retrospective study, there has been no
standardised treatment protocol, and there is the risk for selection
bias. There was no centralised pathology review in this study, but
all slides were from large referral hospitals with dedicated
gynaecological pathologists. This makes the results of this study
applicable to daily practice in such hospitals.
CONCLUSION
In conclusion, this study shows the prognostic value of L1CAM
expression in stage I EECs and advanced-stage EECs, but not in
NEECs. The expression of L1CAM was associated with the
presence of nodal disease, non-endometrioid histology, grade 3
histology, LVSI, and with a high risk of distant disease recurrence.
Implementation of L1CAM expression in clinical practice could
improve the postoperative selection of high-risk carcinomas. Both
the value of L1CAM expression in the preoperative selection of
high-risk carcinomas and the consequences of L1CAM expression
on the use of and response to chemotherapy should be studied.
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